Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants.
Saved in:
| Title: | Pneumococcal carriage following PCV13 delivered as one primary and one booster dose (1 + 1) compared to two primary doses and a booster (2 + 1) in UK infants. |
|---|---|
| Authors: | Goldblatt D; Infection, Immunity and Inflammation Department, UCL Great Ormond Street Institute of Child Health Biomedical Research Centre, London, United Kingdom. Electronic address: d.goldblatt@ucl.ac.uk., Andrews NJ; Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, United Kingdom., Sheppard CL; Respiratory and Vaccine Preventable Bacteria Reference Unit, UK Health Security Agency, London Vaccine Preventable Bacteria Section, National Infection Service Public Health England Colindale, United Kingdom., Rose S; Respiratory and Vaccine Preventable Bacteria Reference Unit, UK Health Security Agency, London Vaccine Preventable Bacteria Section, National Infection Service Public Health England Colindale, United Kingdom., Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom and NIHR Oxford Biomedical Research Centre, United Kingdom., Roalfe L; Infection, Immunity and Inflammation Department, UCL Great Ormond Street Institute of Child Health Biomedical Research Centre, London, United Kingdom., Southern J; Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, United Kingdom., Robinson H; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom and NIHR Oxford Biomedical Research Centre, United Kingdom., Pearce E; Infection, Immunity and Inflammation Department, UCL Great Ormond Street Institute of Child Health Biomedical Research Centre, London, United Kingdom., Plested E; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom and NIHR Oxford Biomedical Research Centre, United Kingdom., Johnson M; Infection, Immunity and Inflammation Department, UCL Great Ormond Street Institute of Child Health Biomedical Research Centre, London, United Kingdom., Litt DJ; Respiratory and Vaccine Preventable Bacteria Reference Unit, UK Health Security Agency, London Vaccine Preventable Bacteria Section, National Infection Service Public Health England Colindale, United Kingdom., Fry NK; Immunisation and Vaccine Preventable Diseases, UK Health Security Agency, United Kingdom., Waight P; Infection, Immunity and Inflammation Department, UCL Great Ormond Street Institute of Child Health Biomedical Research Centre, London, United Kingdom., Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom and NIHR Oxford Biomedical Research Centre, United Kingdom., Miller E; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, United Kingdom. |
| Source: | Vaccine [Vaccine] 2023 May 05; Vol. 41 (19), pp. 3019-3023. Date of Electronic Publication: 2023 Apr 10. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
